NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
Akeso
Jiangsu Cancer Institute & Hospital
Betta Pharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.
TYK Medicines, Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
EQRx International, Inc.
Istituto Clinico Humanitas
IO Biotech
Tongji Hospital
Shenzhen People's Hospital
HiberCell, Inc.